NCT05706025
Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer
Enrolling by Invitation
NAAges 45+InterventionalDiagnosticUniversity of Colorado, DenverInvestigator-initiated
~60 participants
Updated 2025-04-06 on ClinicalTrials.gov
What's tested:EnteroTracker
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Study Esophageal Mucosal Samples using Enterotracker Device
Measured over 2 years
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesColorado1
Study leadership
- Sachin Wani, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Study Esophageal Mucosal Samples using Enterotracker Device2 years
Capture esophageal mucosal samples in at least 50% of the test subjects using the EnteroTracker®.
- Testing Tolerability via "Post-Procedure Tolerability Survey"2 years
At least 50% of subjects describe the EnteroTracker® as "Satisfactory" from taking a "Post-Procedure Tolerability Survey".
- Testing difference in Biomarkers between Control and BE/EAC patients2 years
At least one biomarker differentiated between BE/EAC patients and control subjects in at least 50% of test subjects. Samples will be analyzed for various biomarkers including proteins, DNA, RNA and/or methylation of DNA.